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Abstract
The kidneys serve an essential regulatory role in most of the animals, including verte-
brates and some invertebrates. They are important in the urinary system and also serve 
homeostatic functions like regulation of electrolytes, maintenance of acid-base balance 
and regulation of blood pressure (via maintaining salt and water balance). They also 
serve as natural filter of the blood and remove wastes that are diverted to the urinary 
bladder. By producing urine, the kidneys excrete wastes such as urea and ammonia. The 
kidneys are responsible for reabsorption of water, glucose, amino acids and trace ele-
ments. They also produce hormones including calcitriol, renin and erythropoietin. The 
kidney is approximately 11–14 cm long, 6 cm wide and 4 cm thick. Each adult kidney 
weighs between 125 and 170 g in males and between 115 and 155 g in females. The left 
kidney is typically slightly larger than the right kidney. Each kidney is made up of about 
1 million microprocessor units called nephrons.
Keywords: polycystic kidney disease, renal failure, single nucleotide polymorphism, 
polymerase chain reaction, disease complications
1. Introduction
The kidneys play an essential regulatory role in animals and are responsible for reabsorp-
tion of water, glucose, amino acids and trace elements. They also produce hormones includ-
ing calcitriol, renin and erythropoietin. The kidney is approximately 11–14 cm long, 6 cm 
wide and 4 cm thick. Each adult kidney weighs between 125 and 170 g in males and between 
115 and 155 g in females. The left kidney is typically slightly larger than the right kidney [1] 
(Figure 1). Each kidney is made up of about 1 million microprocessor units called nephrons. 
© 2018 The Author(s). Licensee InTech. This chapt r is distributed under the terms of the Creative Comm s
Attribution L cense (http://creativecommons. /licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
The nephron is the basic structural and functional unit of a kidney [3]. Each nephron has an 
initial filtering component composed of a glomerulus and Bowman’s capsule, which is con-
nected to a long convoluted tubule lined by transporting epithelia.
Sodium chloride, potassium and glucose are filtered and reabsorbed along with water in the 
nephron back into the bloodstream. This maintains a correct balance of trace element within 
the blood, which assists in blood pressure regulation and normal levels of blood sugars. 
Hence, the kidneys are found to play a crucial role in regulating the amount of water and 
chemicals (electrolytes) in the body such as sodium, potassium and phosphorus [4].
1.1. Different types of kidney diseases
Usually both the kidneys are affected by various forms of diseases and then the waste prod-
ucts and excess fluid build up, causing severe swelling and symptoms of uremia (kidney 
failure). They are congenital kidney disease, hereditary kidney disorders and acquired kidney 
diseases.
1.1.1. Congenital disease
It involves malformation of the genitourinary tract, usually leading to some type of obstruc-
tion that subsequently produces infection and/or destruction of kidney tissue, which may 
eventually progress to chronic kidney failure. For example, horseshoe kidney, also known as 
ren arcuatus (in Latin), renal fusion or super kidney, is a congenital disorder affecting about 
1 in 500 people [5, 6].
1.1.2. Hereditary disorders
Hereditary diseases are Alport's syndrome or hereditary nephritis, primary hyperoxaluria, 
cystinuria and polycystic kidney disease (PKD). The chapter found that polycystic kidney 
disease is more common among the population.
Figure 1. Structure and location of kidney. Source: [2] (http://www.sugarbp.org/kidneystucture_diabetes.htm).
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1.1.2.1. Polycystic kidney disease (PKD)
Epithelial cell polarity is vitally important for correct function of different tubule segments [3]. 
Cell polarity defects have been linked to a number of hereditary kidney diseases including 
polycystic kidney diseases (PKDs) characterized by the accumulation of fluid-filled cysts in the 
cortex and medulla [7–10]. There are two types of PKDs. They are autosomal dominant polycys-
tic kidney disease (ADPKD) and autosomal recessive polycystic kidney disease (ARPKD) [10].
1.1.3. Acquired kidney diseases
These diseases are numerous and are generally known as nephritis (inflammation of the 
kidney). The most common type of nephritis is glomerulonephritis and has many causes. 
The acquired kidney diseases are renal agenesis, multicystic dysplastic kidney, renal dys-
plasia, diabetic nephropathy, glomerulonephritis, hydronephrosis, interstitial nephritis, kid-
ney stones, kidney tumors: Wilms tumor and renal cell carcinoma, lupus nephritis, minimal 
change disease (MCD), nephrotic syndrome, pyelonephritis and renal failure.
2. Renal failure
In renal failure, the kidneys lose their normal function due to various factors including infec-
tions, autoimmune diseases, diabetes and other endocrine disorders, cancer, and toxic chem-
icals [11]. Genetic variability on the development of renal failure is becoming clearer and 
emphasizes the need to elucidate the genetic basis for renal diseases and associated complica-
tions. Studies on genetic variability in renal failure would lead to better understanding of dif-
ferent phenotypes observed in polycystic kidney disease and would enable us to determine 
whether a patient is genetically predisposed to such complications.
2.1. Acute renal failure
Acute kidney injury (AKI), previously called acute renal failure (ARF), is a rapid loss of kidney 
function due to low blood volume from any cause, exposure to substances harmful to the kid-
ney and obstruction of the urinary tract [12, 13]. Elevated blood urea nitrogen and creatinine 
or inability of the kidneys to produce sufficient amounts of urine is noted in these patients.
2.2. Stage 5 chronic kidney diseases
Stage 5 CKD is often called end stage renal disease (ESRD). The symptoms of Stage 5 CKD 
are:
• Increase in serum creatinine or protein in the urine are observed.
• The patients develop hypertension or congestive heart failure due to fluid overload and pro-
duction of vasoactive hormones created by the kidney via the RAS (renin-angiotensin system).
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• Urea accumulates, leading to azotemia and ultimately uremia. Urea is excreted by sweat-
ing and crystallizes on skin (“uremic frost”) (http://en.wikipedia.org/wiki/Chronic_kid-
ney_disease; “Chronic Kidney Disease”. medscape.) [14].
• Later this progresses to secondary hyperparathyroidism, renal osteodystrophy and vascu-
lar calcification that further impair cardiac function.
• Metabolic acidosis, due to accumulation of sulfates, phosphates, uric acid, etc., leads to 
excitability of cardiac and neuronal membranes by promoting hyperkalemia [15].
People with chronic kidney disease (hyperlipidemia) suffer from accelerated atherosclerosis 
and are likely to develop cardiovascular disease than the general population [16].
3. Polycystic kidney disease (PKD)
There are two forms of PKD:
(i) Autosomal dominant polycystic kidney disease (ADPKD)
(ii) Autosomal recessive polycystic kidney disease (ARPKD)
3.1. Autosomal dominant polycystic kidney disease (ADPKD)
Autosomal dominant polycystic kidney disease occurs worldwide and in all races. ADPKD 
is one of the most commonly inherited conditions in humans with an incidence of 1:500 to 
1:1000 [17, 18]. It is genetically heterogeneous with two genes identified: PKD1 (16p13.3) and 
PKD2 (4q21) [9, 19, 20].
3.2. Autosomal recessive polycystic kidney disease (ARPKD)
ARPKD is uncommon and occurs primarily in neonates and children. The gene responsible 
for ARPKD (PKHD1) has recently been identified on chromosome 6. Fibrocystin is defective 
in ARPKD [21, 22]. The occurrence of ADPKD is most common when compared to ARPKD 
and the mean age of onset is between 30 and 40 years. Both men and women are equally 
affected [23]. Hence the present study is also focused on PKD1 and PKD2 gene polymorphism 
in autosomal dominant polycystic kidney disease subjects and control subjects among South 
Indian population.
Tables 1 and 2 show polymorphism study in PKD1 and PKD2 gene among various popula-
tions on both national and international level.
3.3. Pathogenesis and genetics of polycystic kidney disease (PKD)
Abnormalities in gene expression, cell polarity, fluid secretion, apoptosis and extracellular 
matrix have also been described in PKD [17, 34–36]. ADPKD is one of the most common 
Mendelian disorders in humans [37, 38] and the most frequent genetic cause of renal failure 
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in adults. ADPKD is a genetically heterogeneous condition [39], which is caused by mutations 
in one of the three genes: PKD1 on chromosome 16 accounts for 85% of cases, whereas PKD2 
on chromosome 4 accounts for 15% and mutations in the PKD3 gene are rare [40]. Hence the 
present study is focused on PKD1 and PKD2 genes in patients with ADPKD among South 
Indian (Madurai) population.
3.4. Chromosomal location of PKD1 and PKD2 gene
PKD1 has been mapped to the short arm of the 16th (16p13.3) chromosome, which encodes 
a protein called polycystin-1. The PKD1 gene is very large in size, consisting of 46 exons 
distributed over 52 kb of genomic DNA [41]. The gene encodes a 14.1-kb mRNA transcript 
to be translated into a protein composed of 4302 amino acids transcript with an open read-
ing frame (ORF) of 12,909 bp [42] (Figure 2). The PKD2 gene maps to chromosome 4q21–23 
(Figure 3). The PKD2 gene encodes a protein, polycystin-2, which is composed of 968 amino 
acids [45]. The interaction of polycystin-1 and polycystin-2 in renal tubules promotes normal 
development and function of the kidneys [46].
Author and year Gene Population Mutation
Sumathy [24] PKD1 Indian PKD1 C-T or G-A, SSCP
Nair et al. [25] ACE, Nellore, Andhra Pradesh I/D polymorphism
Elumalai et al. [26] eNOS, VNTR South Indian a/b polymorphism
Veeramuthumari and Isabel [27]* PKD1 South Indian (Madurai) Ala/Val (C/T) polymorphism
Veeramuthumari et al. [28]* PKD2 South Indian (Madurai) Arg/Pro (G/C) polymorphism
*Current study.
Table 1. National reports of PKD1 and PKD2 gene polymorphism.
Author and Year Gene Population Mutation
Hateboer et al. [29] PKD2 Spain, Netherlands, UK, 
Bulgaria, Australia
C-T substitution, deletion, nonsense mutation, 
frameshift, missense, splice mutation
Koptides et al. [30] PKD1 & 
PKD2
Cyprus Mutation in exon 24, mutation in exon 1
PKD1 & 
PKD2
Slovenia Frameshift/missense mutation; nonsense 
mutation
Son et al. [31] PKD1 Devis, USA CT transversion (SNP)
PKD1 & 2 US Mutation
Lee et al. [32] PKD1 Taiwan C → A transversion
Galeano et al. [33] PKD1 Belgium SNP
Table 2. International reports of PKD1 and PKD2 gene polymorphism.
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Figure 2. Chromosomal location of PKD1 gene. Source: [43] http://ghr.nlm.nih.gov/gene/PKD1.
Figure 3. Chromosomal location of PKD2 gene. Source: [44] http://ghr.nlm.nih.gov/gene/PKD2.
3.4.1. Polycystin-1
The PKD1 gene codes for polycystin-1 (PC-1) and plays a vital role in cell-cell and cell-matrix 
interaction [41]. Thus, a defect in polycystin-1 leads to the alteration in the differentiation of 
epithelial cells and abnormal phenotypic expression of autosomal dominant polycystic kidney 
disease (ADPKD). The proteins encoded by the PKD1 and PKD2 genes define a new family. 
The polycystins play an important role in a variety of biological processes including fertiliza-
tion, ion transduction and mechanosensation. Polycystin-1 is an integral membrane protein, 
which is predicted to contain an array of distinct protein motifs, including two leucine-rich 
repeats flanked by cystine-rich domains. Many of these motifs are involved in protein-protein 
or protein-carbohydrate interaction, which raises the possibility of polycystin-1, as a receptor 
for a yet unidentified ligand. The carboxyl terminus of polycystin-1 is located in cytoplasm 
and contains coil-coil domains and mediates the protein-protein interaction as well as several 
potential sites of phosphorylation. Polycystin-1 is expressed in many tissues, including the 
kidney, brain, heart, bone and muscles [47]. Foggensteiner et al. [48] have reported that sev-
eral studies have identified polycystin-1 in the plasma membrane of tubular epithelial cells, in 
the distal nephron and in the collecting duct. The defect of polycystin-1 might lead to altera-
tion in differentiation of epithelial cells and abnormal phenotypic expression of ADPKD [49].
3.4.2. Polycystin-2
Polycystin-2 is also widely expressed in many tissues, particularly the kidney, heart, ovary, 
testis, vascular smooth muscle and small intestine [47]. In the kidney, polycystin-2 like 
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polycystin-1 is expressed in all nephron segments, with the possible exception of the thin 
limbs but absent from glomeruli. Several studies have shown that the polycystin-2 chan-
nel conducts divalent cations including calcium and that this activity can be stimulated by 
calcium on the cytosolic side.
3.4.3. Fibrocystin/polyductin
The protein encoded by the PKHD1 gene has been named polyductin or fibrocystin and is 
composed of 4074 amino acids [22]. Polyductin/fibrocystin is predicted to be a membrane 
protein consisting of a large extracellular domain, a single transmembrane segment and a 
short carboxyl-terminal tail. Polyductin is a novel protein, although it has some similarities to 
other proteins in the database.
3.5. Mechanism of cyst formation
Cysts will form in these patient’s kidneys and several studies suggest that the cells that line 
these cysts will have lost both functional copies of a polycystin gene [50, 51]. Defects in the 
genes encoding PC1 or PC2 lead to aberrant gene transcription, cell proliferation and ion 
secretion, which in turn result in the formation of fluid-filled cysts. These cysts lead to the 
displacement of the normal renal parenchyma and the formation of a cyst-filled kidney with 
reduced functional capacity (Figure 4).
3.6. ADPKD-associated common complications
Common complications associated with ADPKD are hypertension, hematuria, urinary tract 
infection, renal calculi, cardiac valve abnormalities, diabetes, hernia of the anterior abdominal 
wall and cerebral berry aneurysms [29, 53]. Hematuria is the presence of red blood cells (RBCs) 
in the urine. In microscopic hematuria, the urine appears normal to the naked eye, but exami-
nation with a microscope shows a high number of RBCs [54]. Diabetic nephropathy (neuropatia 
diabetica) also known as Kimmelstiel-Wilson syndrome, or nodular diabetic glomerulosclerosis 
[55] and intercapillary glomerulonephritis, is a progressive kidney disease. Anterior abdomi-
nal wall hernias, also known as ventral hernias, are involved in the protrusion of part of the 
peritoneal sac through a defect in the muscle layers of the anterior abdominal wall [56]. A 
cerebral or brain aneurysm is a cerebrovascular disorder in which weakness in the wall of a 
cerebral artery or vein causes a localized dilation or ballooning of the blood vessel [57].
Figure 4. Cyst formation in nephron, kidney and at cellular level [52].
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Clinically, PKD is characterized by progressive formation and enlargement of cysts lead-
ing to end-stage renal disease (ESRD) in late middle age. Overall, ADPKD accounts for 
approximately 5–10% of ESRD [58]. Hypertension occurs in 50–75% of patients prior to renal 
insufficiency and it is thought to accelerate the decline in renal function [59, 60]. Systemic 
hypertension is also very common, occurring in more than 75% of patients. Increased blood 
pressure (BP) has been attributed to activation of the renin-angiotensin system, but a primary 
defect in blood vessels may also exist [61].
3.7. Method of diagnosis and screening
Nowadays, ADPKD is studied by ultrasound, CT or MRI with multiple cysts that are generally 
visible that increase in size and number with age [62]. ADPKD is typically diagnosed in adults by 
the detection of bilaterally enlarged polycystic kidneys using transabdominal ultrasound scan-
ning. The diagnosis of ADPKD is established primarily by imaging studies of the kidney [53]. 
For diagnosis of ADPKD, computer tomography (CT) has been used effectively, which has also 
revealed multiple cysts in kidneys and left ovary and aneurysm in the brain [53].
3.7.1. Treatment
When renal function, measured by glomerular filtration rate, is persistently poor, dialysis 
and kidney transplantation could be done. Cotran et al. [63] have stated that a common 
symptom of kidney stones is a sharp pain in the medial/lateral segments of the lower back. 
Approximately 50% of afflicted individuals have been shown to develop end-stage renal dis-
ease requiring dialysis or kidney transplantation before the age of 60 [8].
3.7.2. Trends in potential therapies and clinical trials
Until now, therapy for ADPKD has been directed toward limiting its complications. Cardiovascular 
complications, related to hypertension, are a major cause of morbidity and mortality. A major 
problem in therapeutic interventions in ADPKD is that this is a very slowly evolving condition, 
and GFR is well maintained until relatively late in the course of the disease at the age of 40. Better 
understanding of signaling pathways and cellular changes associated with ADPKD has suggested 
possible therapies to directly inhibit the development or growth of cysts, some of which are now 
being tested in clinical trials [64]. A stable somatostatin analogue, octreotide, has been shown to 
be effective at limiting progression in liver and kidney cystic disease in a rat model of PKD [65].
Advanced-stage ADPKD patients frequently receive a renal transplant without removal of the 
affected cystic kidneys, without side effects. Rapamycin is often used to prevent transplant 
rejection. The absence of polycystin permits excessive kinase activity in the mTOR pathway 
and the development of renal cysts [66]. Patients treated with rapamycin have been reported 
to show a statistically significant reduction in native polycystic kidney size over a period of 
24 months compared with patients treated with other antirejection drugs. Other targets for 
therapy include triptolide, a compound derived from a traditional Chinese herbal therapy, 
which blocks glycosyl ceramide synthesis [67].
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4. Methodology to be followed for the discovery of single nucleotide 
polymorphism in polycystic kidney disease
Genomic DNA preparation: [68, 69].
Reagents required: phosphate buffer saline (PBS), red blood cell (RBC) lysis buffer, cell lysis 
buffer (CLB), ammonium acetate, isopropyl alcohol, 70% ethanol, TE buffer
Procedure: the blood samples were thawed at room temperature and 300 μl of blood was 
transferred to centrifuge tubes. Equal volume of PBS was added to it and incubated for 20 min 
and centrifuged at 3000 rpm for 5 min. The supernatant was removed and the pellet was 
resuspended in 900 μl of RBC lysis buffer and mixed thoroughly. This was centrifuged at 
3000 rpm for 5 min and the supernatant was discarded. To the pellet 600 μl of ice-cold cell, 
lysis buffer was added and mixed well, and then 200 μl of ammonium acetate was added to 
the mixture to precipitate the proteins and centrifuged at 3000 rpm for 7 min. The supernatant 
was separated and 1000 μl of isopropanol was added and the tube was inverted till the DNA 
was precipitated and centrifuged at 7000 rpm for 2 min. The precipitated genomic DNA was 
washed with 600 μl of 70% ethanol and allowed to air dry. The DNA was resuspended in TE 
buffer and stored at −20°C.
Electrophoretic analysis of genomic DNA: the isolated DNA was confirmed by 0.7% agarose 
gel electrophoresis [68, 69].
Reagents required: Tris-boric acid EDTA buffer (TBE), gel loading dye, ethidium bromide 
(ETBR).
Equipment required: electrophoresis tank, power pack, voltage (100 V), gel documentation 
apparatus, UV-transilluminator.
Principle: electrophoresis refers to the separation of macromolecules of different size by 
application of a constant electric field (100 V) onto the DNA fragments placed in a matrix 
of polymerized agarose. As the DNA molecule is negatively charged and travels toward the 
anode, it is loaded at the cathode end. The speed of migration of the fragments has an inverse 
relation with the size of DNA. The separated fragments are visualized by staining the gels 
with an intercalating dye (ethidium bromide), which fluoresces under UV light. Acrylamide 
gels are used for separation of small fragments of DNA (5–500 bp). Agarose gels can resolve 
DNA fragments varying in size from 200 bp to about 50 kb depending upon the concentration 
of agarose in the gel.
Procedure: electrophoresis tank was filled with the 1× TBE buffer and the gel was immersed 
into the tank containing the buffer. Agarose gel (0.7%) was prepared with ethidium bromide 
and the gel was allowed to run for 1 hour at 80–100 V as pulse voltage. 20 μl of DNA sam-
ple was loaded with loading dye (bromophenol blue) in the wells. When bromophenol blue 
dye reached three fourth of the gel length, the power was shut down, and DNA bands were 
observed using gel documentation apparatus and photographed.
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4.1. Genetic analysis
4.1.1. Polymerase chain reaction (PCR) for PKD1 gene (C/T polymorphism)
Amplification of isolated DNA using the following primers 5′-AGCTGTACGCCCTCACTGG-3′ 
(forward) and 5′-GTGACAGGTGCCAGGACTC-3′-(reverse). PCR was performed using 
genomic DNA (50 ng), Taq polymerase (1 U), dNTPs (10 mM) and each primers (10 μM) 
[37, 69, 70].
PCR condition used:
The PCR product (298 bp) was confirmed by 1.8% of agarose gel electrophoresis. The ampli-
fied product was subjected to RFLP analysis.
4.1.1.1. Restriction fragment length polymorphism (RFLP)
Amplified PCR product is digested with restriction enzyme AvaII, incubated the reaction mix-
ture at 37°C for 3 hours and inactivated by incubation at 64°C for 15 min. The enzyme cuts 
the sequence if “T” was at position 4058. The digested fragments (298, 225 and 73bp) were 
confirmed by 1.2% agarose gel [37, 69, 70].
Restriction fragment length polymorphism (RFLP)
4.1.2. Polymerase chain reaction (PCR) for PKD2 gene (G/C polymorphism)
Amplification of PKD2 gene using the following primers 5′-CGCGCCGGACGCCAGTGACC-3′ 
(forward) and 5′-GCCGGCCGTTCTGGTTCGT-3′ (reverse). PCR was performed using 
genomic DNA (50ng), Taq polymerase (1U) and dNTPs (10mM) [69, 71].
Initial denaturation 94°C 5 min
Denaturation 94°C 30 s
Annealing 61°C 30 s 35 cycles
Extension 72°C 30 s
Final extension 72°C 7 min
Restriction site for AvaII 5′….G↓GWCG ….3′
3′….CCWG↑G….5′
Source: E. coli strain that carries the AvaII gene from Anabaena variabilis
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PCR condition used:
The PCR product (279 bp) is confirmed by 1.8% of agarose gel electrophoresis. The amplified 
product was subjected to RFLP analysis.
4.1.2.1. Restriction fragment length polymorphism (RFLP)
Amplified product is digested with restriction enzyme BanII, incubated the reaction mixture 
at 37oC for 2 hours and inactivated by incubation at 65oC for 20 min. The enzyme cuts the 
sequence if “C” was at position 28. The digested segments were confirmed by 1.2% agarose 
gel [69–71]).
Sequencing: PKD1 gene (C/T) and PKD2 gene (G/C) single nucleotide polymorphism was 
sequenced by automated sequencer (Chromous Biotech, Chennai).
Allelic frequency calculation: allelic frequency was calculated by using Hardy-Weinberg 
Equilibrium. The phenotype and genotypic frequencies in sexually reproducing, diploid 
organisms could be determined by applying simple algebraic expression.
  p + q = 1 (1)
where p is the frequency of dominant allele and q is the frequency of recessive allele.
Statistical analysis:
• Pearson Chi-square (χ2) test was performed to find the statistical significance of genotypes 
and the gene frequency between the control group and ADPKD patients.
• Odds ratio (OR) was calculated for allelic frequency.
• Heterozygosity was calculated for the control subject and PKD patients.
Restriction site for BanII: 5′ G RGCY↓ C 3′
5′ C↑YCGR G 5′
Source: E. coli strain that carries the cloned BanII gene from Bacillus aneurinolyticus.
Initial denaturation 94°C 5 min
Denaturation 94°C 30 s
Annealing 61°C 30 s 35 cycles
Extension 72°C 30 s
Final extension 72°C 7 min
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5. Identifications of single nucleotide and polymorphisms and 
discussions
5.1. Genetic analysis
ADPKD is one of the most common genetic diseases in humans, affecting all ethnic groups 
with a prevalence of 1 in 500 to 1000 individuals [9, 18, 19, 72]. The disease is characterized 
by the progressive formation and enlargement of fluid-filled cysts in both kidneys due to 
mutations in PKD1 (85%), PKD2 (15%) and PKD3 (rare) that leads to renal failure [73]. Cyst 
development involves impairments in a wide range of cellular processes including increased 
proliferation of the renal epithelial cells, fluid transport defects, alterations in tubular base-
ment membrane, altered cell polarity and increased apoptosis [9, 74].
Genomic DNA was isolated from frozen blood of control and ADPKD patients; it was con-
firmed by agarose gel electrophoresis (0.7%). After confirming the presence of genomic DNA, 
most of the prepared gDNA of the 260/280 ratio was found to be 1.8 or 1.9; in a few subjects, the 
DNA showed 2.0, which might be RNA or protein contamination. To avoid that, RNase, prote-
ase was added. Then, it was confirmed and used for PCRanalysis.
5.1.1. Analysis of C/T polymorphism in PKD1 gene
Prepared gDNA when subjected to polymerase chain reaction (PCR), 298bp fragment was 
obtained. The amplified PCR product was subjected to RFLP analysis using AvaII enzyme. 
When “T” allele was present at position 4058, 225bp and 73bp (homozygous mutant -TT), 
heterozygous mutant (CT) 298bp, 225bp and 73bp was obtained, and for homozygous normal 
allele (CC), 298bp fragments were identified (Figure 5). The PCR and RLFP products were 
detected and confirmed by 1.2% agarose gel electrophoresis.
5.2. Genotype and allelic frequency analysis of PKD1 (C/T) gene
The study group comprised 300 ADPKD patients and an equal number of age- and sex-
matched control group. Among them, the C/C genotype was observed in 131 (43.67%) control 
group and in 58 (19.33%) ADPKD patients; C/T genotype in 82 (27.33%) control group and 
in 99 (33%) ADPKD patients; T/T genotype was found in 87 (29%) control group and in 143 
(47.67%) ADPKD patients. The allelic frequency was calculated by using Hardy-Weinberg equa-
tion (p + q = 1) and the study group showed the mutant “T” allele frequency (0.642) to be signif-
icantly higher in ADPKD patients than in the control group (0.425) and the normal “C” allele 
frequency was observed to be significantly decreased in ADPKD patients (0.358) than in the 
control group (0.575). The significant difference (P < 0.05, 9.488, χ2 calculated value = 14.048) 
(Table 3) was noted both in genotype and in allelic frequency between the ADPKD patients 
and control group among South Indian (Madurai) population by using chi-square (χ2) test. 
This work, which coincides with the work done by Constantinides [70] among Caucasian 
and Japanese population, also has revealed the association of C/T4058 polymorphism with 
ADPKD. The PKD1 gene is responsible for causing autosomal dominant polycystic kidney 
disease and it has been recently cloned and sequenced [75]. ADPKD is reported to be a very 
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frequent disorder among Caucasian population with an estimated incidence of approximately 
1:100. It has been shown to be characterized by genetic heterogeneity and three genes have 
been implicated in its pathogenesis called PKD1, PKD2 and PKD3 [76, 77].
The study found that the identification of DNA variation at nucleotide position at 12173 of PKD1 
gene and C or T allele variation in the second position of amino acid codon at 4058 of polycys-
tin-1 observed in 44 Japanese subjects, leading to suggest that these polymorphic alleles would 
be useful for linkage analysis only in specific ethnic groups [41]. It has been also reported that 
the PKD2 gene provides instructions for making a protein called polycystin-2, which is found 
in the kidneys before birth and in many adult tissues. It is also stated that the polycystin could 
be regulated by a larger and somewhat similar protein called polycystin-1, which is encoded by 
PKD1 gene [78].
5.2.1. Analysis of G/C polymorphism in PKD2 gene
Prepared gDNA was subjected to polymerase chain reaction (PCR) and 279bp fragment was 
amplified. The amplified PCR product is digested with the enzyme Ban II. The enzyme acts 
on the “C” variation but not on the “G” variation. If a “C” allele was present at position 83, 
170bp and 109bp were obtained. If it was a homozygous mutant (CC), 170bp and 109bp; 
heterozygous mutant (GC), 279bp, 170bp and 109bp and homozygous normal (GG), 279bp 
fragments were identified. One such variation was at position 83 of PKD2, which was occu-
pied by either G or C at exon 1. Hence, the amino acid residue was changed from arginine 
to proline.
The study also found that BSP12861 restriction enzyme also acts on the “C” variation. This 
enzyme was added to 10 ADPKD patients of amplified PKD2 gene product (279bp). The 
Figure 5. Confirmation of PKD 1 gene polymorphism using 1.2% agarose gel electrophoresis. T/T: homozygous mutant 
(225, 73 bp); C/T: heterozygous mutant (298bp, 225bp, 73bp) ; C/C: homozygous normal (298bp).
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results showed to be like Ban II restriction digestion gene products. If a “C” allele was pres-
ent at position 83, 170bp and 109bp were obtained. If it was homozygous mutant (CC), 170bp 
and 109bp; heterozygous mutant (GC), 279bp, 170bp and 109bp and homozygous normal 
(GG), 279bp fragments were identified (Figure 6). The study was supported by the work of 
Koptides et al., [30]. Koptides et al. demonstrated that both G/C transversion mutation and 
six ‘Cs” insertion mutation in exon 1 of the PKD2 gene of three separate cysts. This mutation 
is expected to cause a translation frameshift, leading to the incorporation of 20 novel amino 
acids before a new stop codon is encountered.
5.3. Genotype and allelic frequency analysis of PKD2 (G/C) gene
The G/G genotype was observed in 137 (45.67%) control group and in 55 (18.33%) ADPKD 
patients, G/C genotype in 84 (28%) control group and in 93 (31%) ADPKD patients and C/C 
genotype in 79 (26.33%) control group and in 152 (50.67%) ADPKD patients. The allelic 
frequency was calculated by using Hardy-Weinberg equation (p + q = 1) and the study group 
showed the mutant “C” allele frequency (0.662) to be significantly higher in ADPKD patients 
than in the control group (0.403) and the normal “G” allele frequency to be significantly 
decreased in ADPKD patients (0.338) than in the control group (0.597). Significant difference 
(P < 0.005, 14.860, χ2 calculated value = 20.451) (Table 4) was noted in genotype and allelic 
frequency between the ADPKD patients. G/C polymorphism at position 83 in exon 1 of PKD2 
gene among South Indian (Madurai) population with ADPKD revealed the “CC” and “GC” 
genotype and the frequency of “C” allele was found to be significantly higher in the ADPKD 
patients compared to the control group. The study has revealed higher frequency of “C” allele 
and lower frequency of “G” allele in ADPKD patients. These results coincide with the work 
of Koptides et al., [30], who identified a polymorphism at position 83, which was occupied by 
either G or C encoding either arginine or proline (R28P).
Figure 6. Confirmation of PKD 2 gene polymorphism using 1.2% agarose gel electrophoresis. C/C: homozygous mutant 
(170 bp, 109 bp); G/C: heterozygous mutant (279 bp, 170, 109); G/G: homozygous normal (279 bp); Lane 1: ladder (100 bp).
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5.4. PKD1 (C/T) and PKD2 (G/C) SNP sequencing
The PKD1 (C/T) and PKD2 (G/C) single nucleotide polymorphism was also confirmed by 
sequencing the PCR amplified gene products of PKD1 and PKD2.
PKD1 (C/T) – Ala/Val. 4058 in Exon 45:
PKD2 (G/C) – Arg/Pro.28 in Exon 1
Genotype Allele frequency χ2 value p value
C/C G/C G/G C G
Control group 
N = 300
79 (26.33%) 84 (28%) 137 
(45.67%)
0.403 0.662 20.79 P < 0.005, 14.860
ADPKD patients 
N = 300
152 (50.67%) 93 (31%) 55 
(18.33%)
0.597 0.338 20.10
C/C: homozygous mutant; G/C: heterozygous mutant; G/G–homozygous normal.
Table 4. Comparison of genotype and allelic frequency of PKD2 gene in control group and ADPKD patients among 
South Indian (Madurai) population.
Ala
A. 5′-AAG CTG TAC GCC CTC ACT GG-3′—Wild type Allele
Val
5′-AAG CTG TAC GTC CTC ACT GG-3′—Mutant Allele
Arg
B. 5′-CG CGC CGG ACG CCA CTG ACC-3′—Wild type Allele
Pro
5′-CG CGC CCG ACG CCA CTG ACC-3′—Mutant Allele
Underlined sequence denotes change in allele leads to new amino acid formation, which is known to be polymorphism.
Genotype Allele frequency χ2 value p value
T/T C/T C/C T C
Control group 
N = 300
87 (29%) 82 (27.33%) 131 
(43.67%)
0.425 0.575 14.16 P < 0.05 9.488
ADPKD patients 
N = 300
143 (47.67%) 99 (33%) 58 
(19.33%)
0.642 0.358 13.93
T/T: homozygous mutant; /T: heterozygous mutant; C/C: homozygous normal.
Table 3. Comparison of genotype and allelic frequency of PKD1 gene in control group and ADPKD patients among 
South Indian (Madurai) population.
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The study coincides with the work of Constantinides et al. [70], Watnick et al. [79] and 
Koptides et al., [30] in Caucasians, Greek-Cypriot populations. The present study reveals that 
these mutation/polymorphism leads to evolution of new alleles and formation of new amino 
acids among South Indian population.
6. Conclusion
Polymorphic DNA markers could be used for presymptomatic and prenatal diagnosis of 
ADPKD. Breuning et al. [80] and Balcells and Criach [81] recommended that prenatal diag-
nosis of PKD by chorionic villi sampling and linkage phase of the DNA markers has been 
established by haplotyping the index family. This testing offers the chance of performing pre-
natal or preimplantation testing in families with severe cases of the disease. Hence the current 
study suggests that genetic testing is very important in determining the severity and progres-
sion of the disease and could possibly be treated with effective drug and delay the end-stage 
renal disease (ESRD). Further research of this study is on DNA based on drug design using 
bioinformatics databases that might help the physicians in providing better treatment for 
polycystic kidney disease patients.
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